Evidence map›Paper›PMID 40639874›Full record

ArticleThe European respiratory journal2025

Modulation of infiltrating CD206

Heng-Jia Liu, Remi Diesler, Joelle Chami, Boxiang Wu, Heng Du, Yue Jin, Melissa Daou, Nicola Alesi, Damir Khabibullin, Caroline Leroux and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The European respiratory journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Current insight into the molecular mechanisms of lymphangioleiomyomatosis.American journal of respiratory cell and molecular biology · 2026
    Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Heng-Jia LiuCenter for Infection, Immunity and Cancer, Zhejiang University-University of Edinburgh Institute, Zhejiang University School of Medicine, Haining, China hengjialiu@intl.zju.edu.cn.
Remi DieslerPulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Joelle ChamiPulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Boxiang WuCenter for Infection, Immunity and Cancer, Zhejiang University-University of Edinburgh Institute, Zhejiang University School of Medicine, Haining, China.
Heng DuPulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Yue JinCenter for Infection, Immunity and Cancer, Zhejiang University-University of Edinburgh Institute, Zhejiang University School of Medicine, Haining, China.
Melissa DaouPulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Nicola AlesiPulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Damir KhabibullinPulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Caroline LerouxClaude Bernard University Lyon 1, University of Lyon, INRAE, UMR754, Member of ERN-LUNG, RespiFil, OrphaLung, Lyon, France.
Vincent CottinDepartment of Respiratory Medicine, National Reference Centre for Rare Pulmonary Diseases, ERN-LUNG, Louis Pradel Hospital, Hospices Civils de Lyon and UMR754, INRAE, Claude Bernard University Lyon 1, Lyon, France.ORCID https://orcid.org/0000-0002-5591-0955
Lloyd G CantleySection of Nephrology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA.
Udo RudloffRare Tumor Initiative, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Elizabeth P HenskePulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

Funding

Mechanisms of immunosuppression in the development and progression of renal disease in Tuberous Sclerosis ComplexR01DK133243 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI Elizabeth P Henske · 2023 to 2026
$2.1M
NIDDK NIH HHS R01 DK133243
6 · The paper itself

Abstract

rationaleLymphangioleiomyomatosis (LAM) is a low-grade neoplasm caused by the proliferation of tuberous sclerosis complex (TSC) 1- or TSC2-deficient LAM cells, resulting in progressive cystic lung disease. The currently approved treatment for LAM delays disease progression but the disease recurs if treatment is discontinued. Therefore, new therapeutic targets and/or strategies are necessary for a cure. Immunosuppressive M2-like macrophages are involved in the progression of various cancers, but their role in the pathophysiology of LAM and as a putative therapeutic target is unknown.

methodsTo identify the different immune cell populations involved in LAM, we generated a single-cell transcriptomic map of pulmonary LAM. Interactions between macrophages and LAM cells were studied using the Visium spatial transcriptomic platform and immunofluorescence staining on human pulmonary LAM specimens. Direct co-culture models were used to characterise the influence of TSC2-deficient cells on macrophage differentiation. The efficacy of targeting M2-like macrophages was assessed in preclinical mouse models of TSC2-deficient subcutaneous tumours treated with RP-182, a synthetic peptide which reprogrammes macrophages towards an antitumour M1-like phenotype.

resultsSingle-cell RNA-sequencing analysis revealed that the majority of macrophages in pulmonary LAM display immunosuppressive markers, including

conclusionLAM cells recruit and polarise macrophages towards an M2 phenotype. M2-like CD206

Indexed as

Lectins, C-TypeLung NeoplasmsLymphangioleiomyomatosisMacrophagesMannose-Binding LectinsReceptors, Cell SurfaceAnimalsCell DifferentiationCoculture TechniquesDisease Models, AnimalDisease ProgressionFemaleHumansMannose ReceptorMiceSingle-Cell AnalysisLectins, C-TypeMannose-Binding LectinsMannose ReceptorReceptors, Cell SurfaceTSC2 protein, humanTsc2 protein, mouseTuberous Sclerosis Complex 2 Protein

Identifiers

PMID40639874
PMCPMC13003767

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.